Authors

Peter Choyke, MD, FACR

Latest:

Dr. Choyke on Recent Developments in Imaging for Prostate Cancer

Peter L. Choyke, MD, FACR, discusses recent developments in imaging for prostate cancer.

Peter Ciszewski

Latest:

Anti-Lung Cancer Compound ASA404 Progresses to Phase III

A pivotal phase III study is currently underway to evaluate the efficacy and safety of Novartis’ novel anti-cancer compound ASA404 in patients with non–small cell lung cancer (NSCLC).

Peter Clark, MD

Latest:

Dr. Clark Discusses Need for Biomarkers in RCC

Peter Clark, MD, professor of medicine and chair of urology, Levine Cancer Institute, Atrium Health, discusses the need for biomarkers in renal cell carcinoma.

Peter Emtage

Latest:

Peter Emtage on the Combination of MEDI4736 and Tremelimumab for NSCLC

Peter Emtage, discusses a phase I open-label study evaluating the safety and tolerability of MEDI4736 in combination with tremelimumab for the treatment of patients with advanced non-small cell lung cancer.

Peter G. Shields, MD

Latest:

A Call for Tackling Smoking Cessation in Cancer Patients

Although the entire medical community recognizes the importance of smoking cessation- both for cancer prevention and cardiopulmonary health-supporting patients in their efforts to cease smoking is generally not done well.

Peter Galle, MD, PhD Johannes Gutenberg University, Mainz

Peter Geon Kim, MD

Latest:

Research Findings Point to Clinical Importance of Clonal Hematopoiesis

Although clonal hematopoiesis of indeterminate potential is recognized as a risk factor for developing hematological neoplasms, a growing body of evidence points to its potential significance in broader clinical scenarios.

Peter J Sciavolino, PhD

Latest:

Distinct Genomic Differences Evident in Younger Patients With Lung Cancer

Clinical trial findings have implications for expanding the use of genomic testingâ€”and thereby potentially increasing treatment optionsâ€”for the younger lung cancer population.

Peter J. Van Veldhuizen, MD

Latest:

ASCO GU 2022: Reflecting on RCC Data With Drs. Toni Choueiri and Peter Van Veldhuizen

OncLive® speaks with Drs. Toni Choueiri and Peter Van Veldhuizen on the latest studies in renal cell carcinoma that were presented during the 2022 Genitourinary Cancers Symposium.

Peter Krein, PhD

Latest:

Peter Krein on Developments in Liquid Biopsies

Peter Krein, PhD, senior director, Medical and Scientific Affairs, QIAGEN, discusses the company's latest advancements in liquid biopsies in comparison to surgical biopsies.

Peter L. Choyke, MD

Latest:

Dr. Choyke on Advancements in Imaging for Prostate Cancer

Peter L. Choyke, MD, FACP, director, Molecular Imaging Program, head, Imaging Section, Center for Cancer Research, National Cancer Institute, discusses advances in imaging for prostate cancer.

Peter L. Choyke, MD, FACP

Latest:

Dr. Choyke on Differences Between PET Scans in Prostate Cancer

Peter L. Choyke, MD, FACP, director, Molecular Imaging Program, head, Imaging Section, Center for Cancer Research, National Cancer Institute, discusses the differences between PET scans in prostate cancer.

Peter L. Salgo, MD, NewYork-Presbyterian Hospital

Peter Langmuir, MD

Latest:

Dr. Langmuir Explains the Side Effects of Vandetanib

Peter Levonian, MS

Latest:

Potential Risks of Genetic Testing in Ovarian Cancer

Peter Levonian, MS, senior genetic counselor, Stanford Medicine, discusses the potential risks of genetic testing in ovarian cancer.

Peter Martin, MD

Latest:

Dr Martin on the Role of BTK Inhibitors in the Management of MCL

Peter Martin, MD, discusses the role of BTK inhibitors in the treatment of mantle cell lymphoma.

Peter Martin, MD, MS, Weill Cornell Medicine

Peter Martin, MD, Weill Cornell Medicine

Peter O'Donnell, MD

Latest:

Dr. O'Donnell on Challenges With PD-L1 Testing in Bladder Cancer

Peter O’Donnell, MD, associate professor of medicine, University of Chicago Medicine, discusses challenges with PD-L1 testing in patients with bladder cancer.

Peter R. Carroll, MD

Latest:

Dr. Peter Carroll on Reducing Unnecessary Biopsies in Prostate Cancer

Peter R. Carroll, MD, MPH, professor and chair of the Department of Urology, University of California San Francisco, talks about the future of biomarker-based testing for prostate cancer.